The Diagnostic Utility of Inhibin Staining in Ovarian Neoplasms

Pelkey, Timothy J.; Frierson, Henry F.; Mills, Stacey E.; Stoler, Mark H.

doi:10.1097/00004347-199804000-00001

Cited by 103 publications

(57 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The present study confirms that the expression of the inhibin a subunit can be detected by immunohistochemistry in sex cord-stromal tumors, 22,23 while it is much rarer in the epithelial cells of ovarian adenocarcinomas. 22,33 The presence of NPY receptors in inhibin-expressing sex cord-stromal tumors may be indicative of an NPY action on the inhibin system; NPY may affect inhibin production and/or release and, as such, play a pathophysiological role in inhibin-producing tumors.…”

Section: Discussionsupporting

confidence: 87%

“…Inhibin is demonstrated by immunohistochemistry in all GCT, LCT, and SLCT, as expected from the literature, [22][23][24] further confirming the histopathological diagnoses. Figure 1 shows two typical examples of GCT stained for inhibin.…”

Section: Inhibin Expressionsupporting

confidence: 87%

“…22,33 The presence of NPY receptors in inhibin-expressing sex cord-stromal tumors may be indicative of an NPY action on the inhibin system; NPY may affect inhibin production and/or release and, as such, play a pathophysiological role in inhibin-producing tumors. Moreover, inhibin may have growth-suppressive functions in these tumors, since inhibin-deficient mice develop malignant sex cord-stromal tumors in very high frequency.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Neuropeptide Y receptor expression in human primary ovarian neoplasms

Körner

Waser

Reubi

2004

Laboratory Investigation

View full text Add to dashboard Cite

Peptide hormone receptors overexpressed in human malignant neoplasms are potential targets for diagnostic scintigraphy and radiotherapy. One such receptor is the neuropeptide Y (NPY) receptor, mediating primarily feeding behavior in the brain but shown recently to play a role in breast cancer. In this study, the presence of NPY receptors was evaluated in another group of gynecological tumors, namely ovarian tumors, using in vitro receptor autoradiography with 125 I-labeled peptide YY and receptor subtype selective analogs. Remarkably, all 10 investigated inhibin-expressing granulosa cell tumors, Leydig cell tumors, and Sertoli-Leydig cell tumors expressed NPY receptors. In contrast, receptors were found in only seven of 22 ovarian adenocarcinomas (32%). Pharmacological characterization of the expressed NPY receptor subtypes in the various tumors revealed the presence of Y1, Y2, or both. In addition, Y1 receptors were observed in intra-and peritumoral blood vessels as well. NPY receptors were not expressed in three ovarian adenomas, three borderline tumors, four fibromas and fibrothecomas, and one dysgerminoma. This is the first time that NPY receptors are described in human ovarian tissue. They may play a role in the pathogenesis and also in the pathophysiology of ovarian malignancies. Moreover, the high incidence and density of NPY receptors in sex cord-stromal tumors suggest that these receptors represent a new potential target for the diagnostic and therapeutic administration of NPY analogs in these tumors.

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Inhibin Expressionsupporting

confidence: 87%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Neuropeptide Y receptor expression in human primary ovarian neoplasms

Körner

Waser

Reubi

2004

Laboratory Investigation

View full text Add to dashboard Cite

show abstract

“…SEC is a rare variant of endometrioid adenocarcinoma, most of which were reported in the ovary and rare cases in the endometrium (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14). It causes important diagnostic difficulties for the pathologist due to its morphologic resemblance to sex cord stromal tumors, especially sertoli cell tumor and sertoli leydig cell tumor.…”

Section: Discussionmentioning

confidence: 99%

Ovarian sertoliform endometrioid adenocarcinoma: A rare variant which causes diagnostic pitfalls

Kankaya¹,

Kahraman²,

Ortaç³

et al. 2015

Ankara Üniversitesi Tıp Fakültesi Mecmuası

View full text Add to dashboard Cite

Sertoliform endometrioid carcinoma (SEC) is a rare variant of endometrioid adenocarcinoma, which causes diagnostic pitfalls due to its morphologic resemblance of sex cord stromal tumors. Herein, we report a case of SEC in the ovary almost all of which consisted of sex-cord like areas and was presumed to be a sertoli cell tumour initially. Immunohistochemical features incompatible with sertoli cell tumour were alerting and extensive sampling revealed a focal component of classical endometrioid carcinoma with anastomosing cribriform areas of more columnar cells. The final diagnosis was sertoliform endometrioid adenocarcinoma. This entity should be kept in mind for all the pathologists and gynaecologic oncologists. Sampling such tumours extensively and confirming the diagnosis by immunohistochemistry using a large antibody panel is requisite for the correct diagnosis and preventing the patient from inappropriate therapies.

show abstract

“…Ovarian hyperthecosis contains lipid-containing cells morphologically identical to the ovarian theca cells [11]. α-Inhibin, a glycoprotein hormone that is produced by ovarian granulosa cells and testicular Sertoli cells usually immunoreacts with cells comprised of sex cord-stromal cells such as granulosa cells and theca cells in the ovary [12]; it intensely labels luteinized theca cells [13]. In our case, α-inhibin reacted with clusters of stromal vacuolated cells, ovarian tumor was tan-yellow in color grossly and contained oil-red-O-positive lipids in the α-inhibin-positive foamy stromal cells.…”

Section: Discussionmentioning

confidence: 99%

Ovarian Endometrioid Adenocarcinoma with Functioning Stroma Accompanied with Endometrial Endometrioid Adenocarcinoma: Immunohistochemical Study and Literature Review

Yuri¹,

Mizokami²,

Kinoshita³

et al. 2013

OJPathology

View full text Add to dashboard Cite

Background: The ovarian tumors with functioning stroma are defined by the morphological presence of endocrine active cells in stroma, and the clinical, biochemical or pathological evidence of endocrine function. Case Report: The ovarian endometrioid adenocarcinoma with functioning stroma accompanied with endometrial endometrioid adenocarcinoma was found in 64-year-old post-menopausal woman complaining abnormal genital bleeding and mammary distention. Her preoperative serum 17ß-estradiol level was high (53.2 pg/ml) while human chorionic gonadotropin (hCG) level was within normal limit. Her right ovary with 8.8 × 5.3 cm in size and tan-yellow in color mostly consisted of solid tumor. Histologically, tumor was composed of estrogen receptor (ER)-and progesterone receptor (PgR)-positive, and androgen receptor (AR)-negative cancerous endometrial cells with aggregates of vacuolated foamy stromal cells resembling luteinized cells. These stromal cells contained lipid droplets, and was immunopositive for α-inhibin and 17ß-estradiol. After surgery, serum 17ß-estradiol level decreased and became normal (14.2 pg/ml). These findings indicate the production of steroid hormone (17ß-estradiol) from the foamy stromal cells and may be correlated with the clinical symptoms. Furthermore, ER-and PgR-positive endometrial endometrioid adenocarcinoma developed synchronously. However, ovary and uterus were totally immunonegative for human chorionic gonadotropin (hCG). Four other cases from the literature including ours are reviewed. Conclusion: Cancer cells were positive for ER and PgR in both ovary and uterus responded to steroid hormone produced by foamy stromal cells, which played a role in proliferation and progression of ovarian and endometrial endometrioid adenocarcinoma, respectively.

show abstract

The Diagnostic Utility of Inhibin Staining in Ovarian Neoplasms

Cited by 103 publications

References 0 publications

Neuropeptide Y receptor expression in human primary ovarian neoplasms

Neuropeptide Y receptor expression in human primary ovarian neoplasms

Ovarian sertoliform endometrioid adenocarcinoma: A rare variant which causes diagnostic pitfalls

Ovarian Endometrioid Adenocarcinoma with Functioning Stroma Accompanied with Endometrial Endometrioid Adenocarcinoma: Immunohistochemical Study and Literature Review

Contact Info

Product

Resources

About